Actively Recruiting

Phase 1
Age: 18Years - 55Years
All Genders
Healthy Volunteers
NCT07230418

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Doses of HRS-3095 Oral Administration in Healthy Subjects, as Well as the Effect of HRS-3095 on CYP3A4 Metabolic Enzymes

Led by Chengdu Suncadia Medicine Co., Ltd. · Updated on 2025-12-03

66

Participants Needed

1

Research Sites

11 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of HRS-3095 oral administration in healthy subjects. This study will also explore food effect and the effect of HRS-3095 on CYP3A4 metabolic enzymes.

CONDITIONS

Official Title

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Doses of HRS-3095 Oral Administration in Healthy Subjects, as Well as the Effect of HRS-3095 on CYP3A4 Metabolic Enzymes

Who Can Participate

Age: 18Years - 55Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Able to comprehend and willing to sign an informed consent form
  • Male and female healthy subjects aged 18 to 55 years
  • Body mass index between 18.0 and 32.0 kg/m2
  • Body weight at least 50 kg for men and 45 kg for women
  • No clinically significant abnormalities in health
  • Women of childbearing potential must agree to use effective contraception methods
Not Eligible

You will not qualify if you...

  • History or presence of circulatory, endocrine, neurological, digestive, respiratory, hematological, immunological, psychiatric diseases, metabolic disorders, or other conditions that could interfere with the trial
  • Any disease affecting drug absorption, distribution, metabolism, or excretion
  • History of recurrent drug allergies or treatment-requiring allergic diseases, or known allergy to any investigational product component
  • Infection requiring systemic antimicrobial therapy within 2 weeks before screening or dosing

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

The Frist Clinical Medicial College of Qingdao University

Qingdao, Shandong, China, 266555

Actively Recruiting

Loading map...

Research Team

H

Hongda Lin

CONTACT

Y

Yifan Li

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here